Reginald Hardy
Chief Executive Officer bei Rythera Therapeutics, Inc.
Profil
Reginald L.
Hardy is the founder of Vical, Inc. (2019), Sano Corp.
(1992), Concordia Pharmaceuticals, Inc. (2003), Brickell Subsidiary, Inc. (2009), and Fresh Tracks Therapeutics, Inc. (2009).
At present, he is the Co-Chief Executive Officer & Director at Rythera Therapeutics, Inc. and Director at Regentys Corp.
Mr. Hardy's former positions include Independent Director at Neurologix, Inc. (2011-2012) and Anchiano Therapeutics Ltd.
(2016-2020), President-Generics Group at IVAX LLC, and Principal at C, Key Pharmaceuticals, Inc., and Hoechst-Roussel Pharmaceuticals, Inc. Mr. Hardy's education history includes an MBA from The University of North Carolina at Greensboro and an undergraduate degree from The University of North Carolina at Charlotte.
Aktive Positionen von Reginald Hardy
| Unternehmen | Position | Beginn |
|---|---|---|
Regentys Corp.
 Regentys Corp. Medical SpecialtiesHealth Technology Regentys Corp. operates as a regenerative medicine firm. It engages in the development and commercialization of medical devices for gastrointestinal applications. The company was founded by Richard C. Bulman Jr., Gerard S. Coombs, Marc Ramer, and Christine V. Sapan in 2013 and is headquartered in Miami Lakes, FL. | Director/Board Member | - |
| Rythera Therapeutics, Inc. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Reginald Hardy
| Unternehmen | Position | Ende |
|---|---|---|
| FRESH TRACKS THERAPEUTICS, INC. | Founder | 02.10.2023 |
| ANCHIANO THERAPEUTICS LTD. | Director/Board Member | 17.05.2020 |
Sano Corp.
 Sano Corp. Pharmaceuticals: MajorHealth Technology Sano Corp. produces plastic membranes. The company is based in Miramar, FL. The company was founded in 1991 by Reginald L. Hardy, Charles J. Betlach. Sano was acquired by Elan Corp. Plc on March 02, 1998 for $391.16 million. | Founder | 01.01.1998 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Founder | - |
Key Pharmaceuticals, Inc.
 Key Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Key Pharmaceuticals, Inc. operates as a subsidiary of Schering-Plough which is engaged in manufacturing, fabricating or processing drugs in pharmaceutical preparations. The company is located in Newark, NJ | Corporate Officer/Principal | - |
Ausbildung von Reginald Hardy
| The University of North Carolina at Greensboro | Masters Business Admin |
| The University of North Carolina at Charlotte | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| FRESH TRACKS THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 12 |
|---|---|
IVAX LLC
 IVAX LLC Pharmaceuticals: MajorHealth Technology IVAX LLC discovers, develops, manufactures, and markets generic pharmaceuticals, respiratory drugs, and cancer treatments. It offers drugs for the treatment of multiple sclerosis, brain cancer, asthma, and epilepsy. The company was founded by Phillip Frost and Jane H. Hsiao in 1987 and is headquartered in Weston, FL. | Health Technology |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Sano Corp.
Sano Corp. Pharmaceuticals: MajorHealth Technology Sano Corp. produces plastic membranes. The company is based in Miramar, FL. The company was founded in 1991 by Reginald L. Hardy, Charles J. Betlach. Sano was acquired by Elan Corp. Plc on March 02, 1998 for $391.16 million. | Health Technology |
Neurologix, Inc.
 Neurologix, Inc. Internet Software/ServicesTechnology Services Neurologix, Inc. engages in the research, development and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system. The company was founded by Martin J. Kaplitt 1978 and is headquartered in Fort Lee, NJ. | Technology Services |
Concordia Pharmaceuticals, Inc.
 Concordia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Concordia Pharmaceuticals Inc. operated as a pharmaceutical development management company. It focuses on the acquisition, in-licensing and development of cancer therapies. The company was founded by Marc Watson and Hubert E. Huckel in 2003 and headquartered in Miami, FL. | Health Technology |
Brickell Subsidiary, Inc.
 Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Health Technology |
Anchiano Therapeutics Ltd.
 Anchiano Therapeutics Ltd. BiotechnologyHealth Technology Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel. | Health Technology |
C/max Capital Corp.
 C/max Capital Corp. Investment ManagersFinance Founded in 1998 by Marc Watson and Kevin Watson, C/max Capital Corp. is a venture capital firm located in Aventura, Florida. | Finance |
Key Pharmaceuticals, Inc.
Key Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Key Pharmaceuticals, Inc. operates as a subsidiary of Schering-Plough which is engaged in manufacturing, fabricating or processing drugs in pharmaceutical preparations. The company is located in Newark, NJ | Health Technology |
| Hoechst-Roussel Pharmaceuticals, Inc. | |
Regentys Corp.
Regentys Corp. Medical SpecialtiesHealth Technology Regentys Corp. operates as a regenerative medicine firm. It engages in the development and commercialization of medical devices for gastrointestinal applications. The company was founded by Richard C. Bulman Jr., Gerard S. Coombs, Marc Ramer, and Christine V. Sapan in 2013 and is headquartered in Miami Lakes, FL. | Health Technology |
| Rythera Therapeutics, Inc. |
